J. Mcmanis

发表

Effects of novel spermine analogues on cell cycle progression and apoptosis in MALME-3M human melanoma cells.

D. Kramer, P. Diegelman, R. Bergeron, 1997, Cancer research.

Structural basis for differential induction of spermidine/spermine N1-acetyltransferase activity by novel spermine analogs.

D. Kramer, S. Vujcic, J. Miller, 1997, Molecular pharmacology.

A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.

Y. Feng, R. Bergeron, C. Porter, 1997, Journal of medicinal chemistry.

The role of charge in polyamine analogue recognition.

J. Vinson, R. Bergeron, C. Porter, 1995, Journal of medicinal chemistry.

Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.

R. Bergeron, N. Bharti, J. Wiegand, 2012, Journal of medicinal chemistry.

Synthesis of cytotoxic spermidine metabolites from the soft coral

B. Ganem, K. Chantrapromma, J. McManis, 1980 .

Relative abilities of bis(ethyl) derivatives of putrescine, spermidine, and spermine to regulate polyamine biosynthesis and inhibit L1210 leukemia cell growth.

R. Bergeron, C. Porter, R. Casero, 1987, Cancer research.

Metabolically programmed iron chelators.

R. Bergeron, N. Bharti, J. Wiegand, 2015, Bioorganic & medicinal chemistry.

Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity

R. Bergeron, N. Bharti, Shailendra Singh, 2011, BioMetals.

The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.

K. Abboud, R. Bergeron, N. Bharti, 2010, Journal of medicinal chemistry.

Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier.

K. Abboud, R. Bergeron, Richard E. Smith, 2003, Chirality.

Synthetic polyamine analogues as antineoplastics.

J. Vinson, R. Bergeron, R. Bortell, 1988, Journal of medicinal chemistry.